Twist Bioscience (NASDAQ: TWST) registers Invenra share resale
Rhea-AI Filing Summary
Twist Bioscience Corporation (TWST) reports that, under a Registration Rights Agreement dated February 11, 2026 with Invenra Inc., it is registering the resale of shares issuable to Invenra under a related Stock Purchase Agreement dated the same day. The company is filing a prospectus supplement to cover these resale shares. An opinion of Orrick, Herrington & Sutcliffe LLP regarding the validity of the shares is included as Exhibit 5.1.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Registration Rights Agreement date: February 11, 2026
Stock Purchase Agreement date: February 11, 2026
8-K signature date: August 19, 2026
+2 more
5 metrics
Registration Rights Agreement date
February 11, 2026
Date of Registration Rights Agreement between Twist Bioscience and Invenra Inc.
Stock Purchase Agreement date
February 11, 2026
Date of Stock Purchase Agreement between Twist Bioscience and Invenra Inc.
8-K signature date
August 19, 2026
Date Twist Bioscience executed the current report
Exhibit 5.1
Opinion of Orrick, Herrington & Sutcliffe LLP
Legal opinion filed in connection with the registered resale of shares
Exhibit 104
Cover Page Interactive Data File
Inline XBRL formatted cover page data
Key Terms
Registration Rights Agreement, Stock Purchase Agreement, prospectus supplement, resale, +1 more
5 terms
Registration Rights Agreement regulatory
"Pursuant to that certain Registration Rights Agreement dated February 11, 2026"
A registration rights agreement is a contract that gives investors the option to have their ownership stakes officially registered with the government, making it easier to sell their shares later. This agreement matters because it provides investors with a clearer path to cash out their investments if they choose, offering more liquidity and confidence in their ability to sell their holdings when desired.
Stock Purchase Agreement financial
"shares issuable pursuant to that certain Stock Purchase Agreement dated February 11, 2026"
A stock purchase agreement is a legal contract that sets the terms for buying or selling shares, specifying the price, number of shares, how payment is made, and any conditions or promises each side must meet. It matters to investors because it defines who owns what, when ownership changes, and what protections or obligations attach to the deal—think of it as a detailed receipt plus the house rules that determine the financial risks and benefits of the transaction.
prospectus supplement regulatory
"the Company is filing a prospectus supplement to register the resale of shares"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
resale financial
"to register the resale of shares issuable pursuant to that certain Stock Purchase Agreement"
Resale is the act of selling an item, asset, or security by someone who previously bought it rather than by the original maker or issuer. It matters to investors because resale activity affects how easily an investment can be sold, the price buyers are willing to pay, and the potential profit or loss — like selling a used car: condition, demand and market rules determine what you can get for it.
Inline XBRL technical
"Cover Page Interactive Data File (formatted as Inline XBRL)"
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.
FAQ
What did Twist Bioscience (TWST) announce regarding Invenra in this 8-K?
Twist Bioscience reported it is filing a prospectus supplement to register the resale of shares issuable to Invenra Inc. under a Stock Purchase Agreement dated February 11, 2026, in accordance with a Registration Rights Agreement with Invenra.
What agreements between TWST and Invenra are referenced in this filing?
The filing references a Registration Rights Agreement dated February 11, 2026 and a Stock Purchase Agreement dated February 11, 2026 between Twist Bioscience and Invenra Inc., under which shares may be issued to Invenra and are now being registered for potential resale.
What type of securities action is Twist Bioscience (TWST) taking here?
Twist Bioscience is registering the resale of shares issuable to Invenra Inc. rather than announcing a new primary offering. The company is using a prospectus supplement to cover these shares pursuant to the existing registration rights arrangement.
Does this Twist Bioscience (TWST) filing describe any earnings or financial results?
No. The filing focuses on registering the resale of shares issued or issuable to Invenra Inc. and related legal opinions. It does not include earnings, revenue figures, or other operating financial results for Twist Bioscience.
AI-generated analysis. How Rhea-AI works. Not financial advice.
